SLAVÍČEK, Lubomír, Tomáš PAVLÍK, Jiří TOMÁŠEK, Zbyněk BORTLÍČEK, Tomáš BÜCHLER, Bohuslav MELICHAR, Rostislav VYZULA, Jana PRAUSOVÁ, Jindřich FÍNEK, Ondřej MÁJEK and Ladislav DUŠEK. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterology. London: BioMed Central, 2014, vol. 14, No 53, p. 1-8. ISSN 1471-230X. Available from: https://dx.doi.org/10.1186/1471-230X-14-53.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
Authors SLAVÍČEK, Lubomír (203 Czech Republic), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Jiří TOMÁŠEK (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Tomáš BÜCHLER (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic), Rostislav VYZULA (203 Czech Republic), Jana PRAUSOVÁ (203 Czech Republic), Jindřich FÍNEK (203 Czech Republic), Ondřej MÁJEK (203 Czech Republic, belonging to the institution) and Ladislav DUŠEK (203 Czech Republic, guarantor, belonging to the institution).
Edition BMC Gastroenterology, London, BioMed Central, 2014, 1471-230X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.365
RIV identification code RIV/00216224:14110/14:00075327
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1186/1471-230X-14-53
UT WoS 000334417600002
Keywords in English Anti-angiogenic therapy; Chemotherapy; Elderly patients; Overall survival; Progression-free survival
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 24/4/2015 12:59.
Abstract
V rámci práce bylo sledováno 3187 pacientů s mCRC léčených bevacizumabem v 1. linii z českého národního registru pacientů s mCRC. Cílem bylo porovnat účinnost a bezpečnost léčby v různých věkových kategoriích.
PrintDisplayed: 27/9/2024 02:27